A federal judge handed Abbott Laboratories another win this week in its yearslong battle over the safety of its formulas for babies born prematurely — a decision that could have implications for ...

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults. The healthcare-products maker on ...

Abbott Laboratories generates revenue through a diversified portfolio including diagnostic systems, generic pharmaceuticals, nutritional products, and medical devices. The company operates a global, ...

Abbott Laboratories (NYSE:ABT) is gearing up to announce its quarterly earnings on Wednesday, 2025-10-15. Here's a quick overview of what investors should know before the release. Analysts are ...

Abbott Laboratories (NYSE:ABT) traded ~3% lower in the premarket on Wednesday after the MedTech giant’s Q3 2025 results slightly fell short of Street forecasts for revenue and the company narrowed its ...

Good morning, and thank you for standing by. Welcome to Abbott's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any ...

Abbott Laboratories (NYSE:ABT) stock fell after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance. The company reported third-quarter sales of $11.37 billion, ...

Oct 15 (Reuters) - Abbott (ABT.N), opens new tab missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its ...

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration launched an investigation into the medical device sector that could lead to ...

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration launched an investigation into the medical device sector that could lead to ...